Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Cannon

Showing results (661-670 of 934) with videos related to

Pageof 94
Sort By:
American Heart Journal|December 9, 2003
Global patterns of use of antithrombotic and antiplatelet therapies in patients with acute coronary syndromes: insights from the Global Registry of Acute Coronary Events (GRACE)Andrzej Budaj, David Brieger, Ph Gabriel Steg, et al.
American Heart Journal|December 16, 2014
Targeted versus standard feedback: results from a randomized quality improvement trialBarbara L Lytle, Shuang Li, David M Lofthus, et al.
Critical Pathways in Cardiology|September 4, 2009
Regional and practice variation in adherence to guideline recommendations for secondary and primary prevention among outpatients with atherothrombosis or risk factors in the United States: a report from the REACH RegistryAmit Kumar, Gregg C Fonarow, Kim A Eagle, et al.
The Lancet. Healthy Longevity|April 1, 2023
Cardiorenal outcomes, kidney function, and other safety outcomes with ertugliflozin in older adults with type 2 diabetes (VERTIS CV): secondary analyses from a randomised, double-blind trialRichard E Pratley, Christopher P Cannon, David Z I Cherney, et al.
American Heart Journal|June 30, 2001
Myoglobin levels at 12 hours identify patients at low risk for 30-day mortality after thrombolysis in acute myocardial infarction: a Thrombolysis in Myocardial Infarction 10B substudyV S Srinivas, C P Cannon, C M Gibson, et al.
Mayo Clinic Proceedings|October 4, 2011
Ethnic differences in cardiovascular risks and mortality in atherothrombotic disease: insights from the Reduction of Atherothrombosis for Continued Health (REACH) registryTelly A Meadows, Deepak L Bhatt, Christopher P Cannon, et al.
Circulation. Cardiovascular Quality and Outcomes|January 12, 2019
Medication Discontinuation in the IMPROVE-IT TrialAnn Marie Navar, Matthew T Roe, Jennifer A White, et al.
Journal of the American College of Cardiology|November 14, 2009
The relative efficacy and safety of clopidogrel in women and men a sex-specific collaborative meta-analysisJeffrey S Berger, Deepak L Bhatt, Christopher P Cannon, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|February 2, 2022
A novel risk score to identify the need for triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention: a post hoc analysis of the RE-DUAL PCI trialBastiaan Zwart, Willem Lambertus Bor, Anne Johanna Wilhelmina Maria de Veer, et al.
Journal of the American College of Cardiology|January 29, 2008
Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 studyOlga A Iakoubova, Marc S Sabatine, Charles M Rowland, et al.
Pageof 94

Showing results (661-670 of 934) with videos related to

Sort By:
Pageof 94
American Heart Journal|December 9, 2003
Global patterns of use of antithrombotic and antiplatelet therapies in patients with acute coronary syndromes: insights from the Global Registry of Acute Coronary Events (GRACE)Andrzej Budaj, David Brieger, Ph Gabriel Steg, et al.
American Heart Journal|December 16, 2014
Targeted versus standard feedback: results from a randomized quality improvement trialBarbara L Lytle, Shuang Li, David M Lofthus, et al.
Critical Pathways in Cardiology|September 4, 2009
Regional and practice variation in adherence to guideline recommendations for secondary and primary prevention among outpatients with atherothrombosis or risk factors in the United States: a report from the REACH RegistryAmit Kumar, Gregg C Fonarow, Kim A Eagle, et al.
The Lancet. Healthy Longevity|April 1, 2023
Cardiorenal outcomes, kidney function, and other safety outcomes with ertugliflozin in older adults with type 2 diabetes (VERTIS CV): secondary analyses from a randomised, double-blind trialRichard E Pratley, Christopher P Cannon, David Z I Cherney, et al.
American Heart Journal|June 30, 2001
Myoglobin levels at 12 hours identify patients at low risk for 30-day mortality after thrombolysis in acute myocardial infarction: a Thrombolysis in Myocardial Infarction 10B substudyV S Srinivas, C P Cannon, C M Gibson, et al.
Mayo Clinic Proceedings|October 4, 2011
Ethnic differences in cardiovascular risks and mortality in atherothrombotic disease: insights from the Reduction of Atherothrombosis for Continued Health (REACH) registryTelly A Meadows, Deepak L Bhatt, Christopher P Cannon, et al.
Circulation. Cardiovascular Quality and Outcomes|January 12, 2019
Medication Discontinuation in the IMPROVE-IT TrialAnn Marie Navar, Matthew T Roe, Jennifer A White, et al.
Journal of the American College of Cardiology|November 14, 2009
The relative efficacy and safety of clopidogrel in women and men a sex-specific collaborative meta-analysisJeffrey S Berger, Deepak L Bhatt, Christopher P Cannon, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|February 2, 2022
A novel risk score to identify the need for triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention: a post hoc analysis of the RE-DUAL PCI trialBastiaan Zwart, Willem Lambertus Bor, Anne Johanna Wilhelmina Maria de Veer, et al.
Journal of the American College of Cardiology|January 29, 2008
Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 studyOlga A Iakoubova, Marc S Sabatine, Charles M Rowland, et al.
Pageof 94